IND
The phase Ib clinical trial is being launched by Cellenkos in partnership with Incyte as part of their LIMBER initiative.
The U.S. Food and Drug Administration cleared an investigational new drug application for ACE1831, an anti-CD20 armed ...
The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...
Advertisement
LAVA-051 consists of two single domain antibodies linked via a short five amino acid glycine-serine linker.
The phase I/II study will assess the safety and tolerability of the drug.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.